Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
EGRX
$62.53
Eagle Pharmaceuticals
$.82
1.33%
EGRX
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus: $0.29
Revenue: $58.00 Mil
Thursday
Oct 31
6:50 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, August 8, 2019
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results
What do you expect when EGRX reports earnings?
Beat
Meet
Miss
Where is EGRX's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
Peers
Regeneron Pharmaceuticals
Celgene
InterCept
Vertex Pharmaceuticals
BioMarin Pharmaceutical
Endo International plc
Johnson & Johnson
Mylan
Zoetis
Perrigo
Expectations
›
Eagle Pharmaceuticals
